Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples
H E Jones, S H Heil, K E O'Grady, P R Martin, K Kaltenbach, M G Coyle, S M Stine, P Selby, A M Arria, G Fischer, H E Jones, S H Heil, K E O'Grady, P R Martin, K Kaltenbach, M G Coyle, S M Stine, P Selby, A M Arria, G Fischer
Abstract
Background: Little is known about the prevalence and severity of smoking in pregnant opioid dependent patients.
Objectives: To first characterize the prevalence and severity of smoking in pregnant patients screened for a randomized controlled trial, Maternal Opioid Treatment: Human Experimental Research (MOTHER), comparing two agonist medications; and second, to compare the MOTHER screening sample to published samples of other pregnant and/or patients with substances use disorders.
Methods: Pregnant women (N = 108) screened for entry into an agonist medication comparison study were retrospectively compared on smoking variables to samples of pregnant methadone-maintained patients (N = 50), pregnant opioid or cocaine dependent patients (N = 240), non-pregnant methadone-maintained women (N = 75), and pregnant non-drug-addicted patients (N = 1,516).
Results: Of screened patients, 88% (n = 95) smoked for a mean of 140 months (SD = 79.0) starting at a mean age of 14 (SD = 3.5). This rate was similar to substance use disordered patients and significantly higher compared to general pregnant patients (88% vs. 22%, p < .001).
Conclusion and scientific significance: Aggressive efforts are needed to reduce/eliminate smoking in substance-abusing pregnant women.
Source: PubMed